



Please type plus sign (+) inside this box →



1124/05

1fw

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/714,591
		Filing Date	November 14, 2003
		First Named Inventor	RAMACHANDRAN, JANAKIRAMAN
		Group Art Unit	1616
		Examiner Name	Not yet assigned
Total Number of Pages in This Submission	5	Attorney Docket Number	GANG-006
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement & SB08a Form (4 pgs.) <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 26 References Postcard	Remarks
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS, LLP		
Signature			
Date	January 21, 2005		

EXPRESS MAIL LABEL NO. EV 519869358 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail No. EV 519869358 US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 	Attorney Docket	GANG-006
	First Named Inventor	RAMACHANDRAN,
	Application Number	10/714,591
	Confirmation No.	3234
	Filing Date	November 14, 2003
	Group Art Unit	1616
	Examiner Name	Not yet assigned
Title: "BACTERIOPHAGE HAVING MODIFIED HOLIN AND USES THEREOF"		

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.


As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. GANG-006 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date:

Jan 21, 2005

By:


Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(fill as many checks as necessary)</i>		Complete if Known	
		Application Number	10/714,591
		Filing Date	November 14, 2003
		First Named Inventor	RAMACHANDRAN, JANAKIRAMAN
		Art Unit	1616
Examiner Name	Not yet assigned		
Sheet 1 of 3	Attorney Docket Number	GANG-006	

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US- 4,957,686		09/18/1990	Norris	
		US- 5,688,501		11/18/1997	Merril, et al.	
		US- 6,121,036		12/19/2000	Ghanbari, et al.	
		US- 6,264,945		07/24/2001	Fischetti et al.	
		US2002/005802		05/16/2002	Nelson et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^a
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 95/31562	11/23/1995	Quest International B.V.		
		WO 95/27043	10/12/1995	Exponential Biotherapies, Inc.		
		WO 01/82945	11/8/2001	New Horizons Diagnostic Corporation		
		GB 829266 A	03/02/1960			
		EP 0403292 A2	06/14/1990	Microbial Development Limited		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Blasi et al. "Two beginnings for a single purpose: the dual-start holins in the regulation of phage lysis" Mol Microbiol. 1996 Aug;21(4):675-82	
		Blasi et al. "The C-terminal sequence of the lambda holin constitutes a cytoplasmic regulatory domain." J Bacteriol. 1999 May;181(9):2922-9	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/714,591		
		Filing Date	November 14, 2003		
		First Named Inventor	RAMACHANDRAN, JANAKIRAMAN		
		Art Unit	1616		
Examiner Name	Not yet assigned				
Sheet	2	of	3	Attorney Docket Number	GANG-006

	Carlton, "Phage therapy: past history and future prospects", R. M., Arch. Immunol. Ther. Exp., 47, 267(1999)	
	Dressman et al. "Lysis and lysis inhibition in bacteriophage T4: rV mutations reside in the holin t gene" J Bacteriol. 1999 Jul;181(14):4391-6	
	Grundling et al. "Holins kill without warning" Proc. Natl. Acad. Sci. USA 98:9348-52 (2001)	
	Hori et al "Construction of self-disruptive <i>Bacillus megaterium</i> in response to substrate exhaustion for polyhydroxybutyrate production", Appl Microbio. Biotech 2002 59 211-216	
	Johnson-Boaz et al. "A dominant mutation in the bacteriophage lambda S gene causes premature lysis and an absolute defective plating phenotype", Mol Microbiol. 1994 Aug;13(3):495-504	
	Jain et al. "Use of lambda phage s and r gene products in an inducible lysis system for <i>vibrio cholerae</i> -and <i>salmonella enteica</i> serovar typhimurium-based DNA vaccine delivery systems", Infect Immun, 68, 986-89 (2000).	
	Kutter, "Bacteriophage Therapy," at www.evergreen.edu/phage/phagetherapy/phagetherapy.html , last updated 07/14/2004	
	Merrill et al "Long-circulating bacteriophage as antibacterial agents", (Proc. Natl. Acad. Sci. USA 93, 3188 (1996)	
	Miller et al. "Bacteriophage T4 genome", Microbiol Mol Biol Rev. (2003) 67(1):86-156	
	Martin et al. "Functional analysis of the two-gene lysis system of the Pneumococcal phage Cp-1 in homologous and heterologous host cells" J. Bacteriol. 180:210-7 (1998)	
	Ramanculov et al. "Functional analysis of the phage T4 holin in a lambda context," Mol. Genet. Genomics 265:345-53 (2001)	
	Ramanculov et al. "Genetic analysis of the T4 holin: timing and topology" Gene 265:25-36 (2001)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/714,591		
		Filing Date	November 14, 2003		
		First Named Inventor	RAMACHANDRAN, JANAKIRAMAN		
		Art Unit	1616		
		Examiner Name	Not yet assigned		
Sheet	3	of	3	Attorney Docket Number	GANG-006

		Sulakvelidze et al. "Minireview Bacteriophage Therapy", Antimicrob Agents Chemotherap, vol. 45, no. 3, pg. 649-659 (2001)	
		Sanders et al "A chloride-inducible gene expression cassette and its use in induced lysis of <i>lactococcus lactis</i> ", Appl Environ. Microbiol. 1997 63 4877-82	
		Smith et al. "Purification and biochemical characterization of the lambda holin" J Bacteriol. 1998 May;180(9):2531-40	
		Tan et al. "Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile." J Med Microbiol. 2001 Jul;50(7):613-9	
		Vukov et al. "Functional analysis of heterologous holin proteins in a lambdaDeltaS genetic background." FEMS Microbiol Lett. 2000 Mar 15;184(2):179-86;	
		Wang et al. "Holins: the protein clocks of bacteriophage infections." Annu Rev Microbiol. 2000;54:799-825	
		Young, "Bacteriophage holins: deadly diversity." J Mol Microbiol Biotechnol. 2002 Jan;4(1):21-36	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2